Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares
Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase…
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK - Pateo Connect revs up for IPO, belching widening losses and slumping margins
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
